Your browser doesn't support javascript.
loading
Efficacy and Safety of Colchicine in Pediatric Pericarditis: A Systematic Review and Future Directions.
Alsabri, Mohammed; Elsayed, Sarah Makram; Elsnhory, Ahmed Bostamy; Abouelmagd, Khaled; Ayyad, Mohammed; Alqeeq, Basel F; Siddiq, Abdelmonem; Soliman, Yousef; Shahid, Muhammad Azan.
  • Alsabri M; Pediatrics Emergency Department, St Christopher's Hospital for Children, Philadelphia, PA, USA. Alsabri5000@gmail.com.
  • Elsayed SM; Emergency department, Al, Thawara Modern General Hospital, Sana'a, Yemen. Alsabri5000@gmail.com.
  • Elsnhory AB; Pediatrics Department, National Heart Institute, Giza, Egypt.
  • Abouelmagd K; Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Ayyad M; Cardiology Department, Faculty of Medicine, Al-Azhar University, New Damietta, Egypt.
  • Alqeeq BF; Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Siddiq A; Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.
  • Soliman Y; Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
  • Shahid MA; Faculty of Medicine, Assiut University, Assiut, Egypt.
Pediatr Cardiol ; 2024 Jul 30.
Article en En | MEDLINE | ID: mdl-39080042
ABSTRACT
Pediatric pericarditis presents challenges in its management, necessitating effective therapeutic interventions. Colchicine, known for its efficacy in adults, requires further investigation for its application and safety in pediatric cohorts. A systematic search across renowned databases identified relevant literature on colchicine use in pediatric pericarditis. Twenty-nine articles underwent rigorous screening, with 18 studies meeting inclusion criteria. Data extraction, quality assessment, and synthesis were conducted meticulously. Included studies comprised case reports, case series, and retrospective cohort studies. Colchicine demonstrated efficacy in reducing recurrence rates and symptom burden, with doses ranging from 0.25 mg/day to 2 mg/day. Adverse events were minimal, predominantly gastrointestinal. Notably, nausea was the most common side effect reported. The safety profile of colchicine was favorable, with rare instances of hepatic and hematologic toxicity. Colchicine emerges as a promising therapeutic option for pediatric pericarditis, demonstrating efficacy in reducing recurrence rates and alleviating symptoms. Its favorable safety profile suggests potential as a preferred long-term therapy. However, further research, including randomized controlled trials, is warranted to confirm its efficacy and safety and explore potential combination therapies.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article